{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:57:27Z","timestamp":1791921447701,"version":"4.3.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["681002"],"award-info":[{"award-number":["681002"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["825759"],"award-info":[{"award-number":["825759"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID-19-inducing virus, SARS-CoV2, is likely to remain a threat to human health unless efficient drugs or vaccines become available. Given the extent of the current pandemic (people in over one hundred countries infected) and its disastrous effect on world economy (associated with limitations of human rights), speedy drug discovery is critical. In this situation, past investments into the development of new (animal-free) approach methods (NAM) for drug safety, efficacy, and quality evaluation can be leveraged. For this, we provide an overview of repurposing ideas to shortcut drug development times. Animal-based testing would be too lengthy, and it largely fails, when a pathogen is species-specific or if the desired drug is based on specific features of human biology. Fortunately, industry has already largely shifted to NAM, and some public funding programs have advanced the development of animal-free technologies. For instance, NAM can predict genotoxicity (a major aspect of carcinogenicity) within days, human antibodies targeting virus epitopes can be generated in molecular biology laboratories within weeks, and various human cell-based organoids are available to test virus infectivity and the biological processes controlling them. The European Medicines Agency (EMA) has formed an expert group to pave the way for the use of such approaches for accelerated drug development. This situation illustrates the importance of diversification in drug discovery strategies and clearly shows the shortcomings of an approach that invests 95% of resources into a single technology (animal experimentation) in the face of challenges that require alternative approaches.<\/jats:p>","DOI":"10.1007\/s00204-020-02787-2","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T18:02:26Z","timestamp":1590256946000},"page":"2263-2272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines"],"prefix":"10.1007","volume":"94","author":[{"given":"Francois","family":"Busquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-1788","authenticated-orcid":false,"given":"Giorgia","family":"Pallocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Rovida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"2787_CR1","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.3389\/fmicb.2018.02766","volume":"9","author":"CM Abreu","year":"2018","unstructured":"Abreu CM, Gama L, Krasemann S et al (2018) Microglia increase inflammatory responses in iPSC-derived human brain spheres. Front Microbiol 9:2766. https:\/\/doi.org\/10.3389\/fmicb.2018.02766","journal-title":"Front Microbiol"},{"issue":"4","key":"2787_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.14573\/altex.1406111","volume":"31","author":"N Alepee","year":"2014","unstructured":"Alepee N, Bahinski A, Daneshian M et al (2014) State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. Altex 31(4):441\u2013477. https:\/\/doi.org\/10.14573\/altex.1406111","journal-title":"Altex"},{"key":"2787_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/antib8030044","author":"JC Almagro","year":"2019","unstructured":"Almagro JC, Pedraza-Escalona M, Arrieta HI, Perez-Tapia SM (2019) Phage display libraries for antibody therapeutic discovery and development. Antibodies (Basel). https:\/\/doi.org\/10.3390\/antib8030044","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"2787_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/026119291404200306","volume":"42","author":"J Bailey","year":"2014","unstructured":"Bailey J, Thew M, Balls M (2014) An analysis of the use of animal models in predicting human toxicology and drug safety. Altern Lab Anim 42(3):181\u2013199. https:\/\/doi.org\/10.1177\/026119291404200306","journal-title":"Altern Lab Anim"},{"issue":"6","key":"2787_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/026119291504300607","volume":"43","author":"J Bailey","year":"2015","unstructured":"Bailey J, Thew M, Balls M (2015) Predicting human drug toxicity and safety via animal tests: can any one species predict drug toxicity in any other, and do monkeys help? Altern Lab Anim 43(6):393\u2013403. https:\/\/doi.org\/10.1177\/026119291504300607","journal-title":"Altern Lab Anim"},{"issue":"1","key":"2787_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14573\/altex.2012.1.003","volume":"29","author":"DA Basketter","year":"2012","unstructured":"Basketter DA, Clewell H, Kimber I et al (2012) A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. Altex 29(1):3\u201391. https:\/\/doi.org\/10.14573\/altex.2012.1.003","journal-title":"Altex"},{"issue":"2","key":"2787_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.14573\/altex.1808181","volume":"36","author":"M Beilmann","year":"2019","unstructured":"Beilmann M, Boonen H, Czich A et al (2019) Optimizing drug discovery by investigative toxicology: current and future trends. Altex 36(2):289\u2013313. https:\/\/doi.org\/10.14573\/altex.1808181","journal-title":"Altex"},{"key":"2787_CR8","unstructured":"Boodman E (2020) Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals. STAT news. https:\/\/bit.ly\/2xwSDKV. Accessed 26 Apr 2020"},{"issue":"2","key":"2787_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.14573\/altex.1502091","volume":"32","author":"M Bouhifd","year":"2015","unstructured":"Bouhifd M, Andersen ME, Baghdikian C et al (2015) The human toxome project. Altex 32(2):112\u2013124. https:\/\/doi.org\/10.14573\/altex.1502091","journal-title":"Altex"},{"key":"2787_CR10","unstructured":"Bruckner T (2020) All COVID-19 clinical trials at a glance. Transparimed. https:\/\/bit.ly\/2Y2Yumt. Accessed 26 Apr 2020"},{"issue":"2","key":"2787_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.14573\/altex.2003241","volume":"37","author":"F Busquet","year":"2020","unstructured":"Busquet F, Kleensang A, Rovida C, Herrmann K, Leist M, Hartung T (2020) New European Union statistics on laboratory animal use\u2014what really counts! Altex 37(2):167\u2013186. https:\/\/doi.org\/10.14573\/altex.2003241","journal-title":"Altex"},{"issue":"4","key":"2787_CR12","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall A, Pirofski LA (2020) The convalescent sera option for containing COVID-19. J Clin Invest 130(4):1545\u20131548. https:\/\/doi.org\/10.1172\/JCI138003","journal-title":"J Clin Invest"},{"key":"2787_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yrtph.2018.04.018","volume":"96","author":"M Clark","year":"2018","unstructured":"Clark M, Steger-Hartmann T (2018) A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans. Regul Toxicol Pharmacol 96:94\u2013105. https:\/\/doi.org\/10.1016\/j.yrtph.2018.04.018","journal-title":"Regul Toxicol Pharmacol"},{"key":"2787_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4050","author":"J Cohen","year":"2020","unstructured":"Cohen J (2020) COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports. Sciencemag. https:\/\/doi.org\/10.1126\/science.abc4050","journal-title":"Sciencemag"},{"issue":"5865","key":"2787_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1126\/science.1154619","volume":"319","author":"FS Collins","year":"2008","unstructured":"Collins FS, Gray GM, Bucher JR (2008) Toxicology. Transforming environmental health protection. Science 319(5865):906\u2013907. https:\/\/doi.org\/10.1126\/science.1154619","journal-title":"Science"},{"issue":"Pt B","key":"2787_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.fct.2016.08.024","volume":"106","author":"R Corvi","year":"2017","unstructured":"Corvi R, Madia F (2017) In vitro genotoxicity testing\u2014can the performance be enhanced? Food Chem Toxicol 106(Pt B):600\u2013608. https:\/\/doi.org\/10.1016\/j.fct.2016.08.024","journal-title":"Food Chem Toxicol"},{"key":"2787_CR17","doi-asserted-by":"crossref","unstructured":"Corvi R, Spielmann H, Hartung T (2019) Alternative approaches for carcinogenicity and reproductive toxicity. In: Balls M, Combes R, Worth A (eds) The history of alternative test methods in toxicology (chapter 3.7). Elsevier Academic Press, London, pp 209\u2013218 (eBook ISBN: 9780128136980, Paperback ISBN: 9780128136973)","DOI":"10.1016\/B978-0-12-813697-3.00024-X"},{"issue":"12","key":"2787_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2533\/chimia.2016.893","volume":"70","author":"P Cosson","year":"2016","unstructured":"Cosson P, Hartley O (2016) Recombinant antibodies for academia: a practical approach. Chim (Aarau) 70(12):893\u2013897. https:\/\/doi.org\/10.2533\/chimia.2016.893","journal-title":"Chim (Aarau)"},{"key":"2787_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fimmu.2012.00343","volume":"3","author":"T Cupedo","year":"2012","unstructured":"Cupedo T, Stroock A, Coles M (2012) Application of tissue engineering to the immune system: development of artificial lymph nodes. Front Immunol 3:343. https:\/\/doi.org\/10.3389\/fimmu.2012.00343","journal-title":"Front Immunol"},{"issue":"4","key":"2787_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14573\/altex.1509081","volume":"32","author":"M Daneshian","year":"2015","unstructured":"Daneshian M, Busquet F, Hartung T, Leist M (2015) Animal use for science in Europe. Altex 32(4):261\u2013274. https:\/\/doi.org\/10.14573\/altex.1509081","journal-title":"Altex"},{"issue":"5","key":"2787_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00204-016-1698-7","volume":"90","author":"M Daneshian","year":"2016","unstructured":"Daneshian M, Kamp H, Hengstler J, Leist M, van de Water B (2016) Highlight report: launch of a large integrated European in vitro toxicology project: EU-ToxRisk. Arch Toxicol 90(5):1021\u20131024. https:\/\/doi.org\/10.1007\/s00204-016-1698-7","journal-title":"Arch Toxicol"},{"issue":"1","key":"2787_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biologicals.2010.12.001","volume":"39","author":"F De Mattia","year":"2011","unstructured":"De Mattia F, Chapsal JM, Descamps J et al (2011) The consistency approach for quality control of vaccines\u2014a strategy to improve quality control and implement 3Rs. Biologicals 39(1):59\u201365. https:\/\/doi.org\/10.1016\/j.biologicals.2010.12.001","journal-title":"Biologicals"},{"key":"2787_CR23","doi-asserted-by":"publisher","DOI":"10.1089\/dst.2012.0006","author":"DRI Drake","year":"2012","unstructured":"Drake DRI, Singh I, Nguyen MN et al (2012) In vitro biomimetic model of the human immune system for predictive vaccine assessments. Disruptive Sci Technol (Feb). https:\/\/doi.org\/10.1089\/dst.2012.0006","journal-title":"Disruptive Sci Technol (Feb)"},{"key":"2787_CR24","unstructured":"EC Research and Innovation (2020) Coronavirus: EU mobilises \u20ac10 million for research. EC.EUROPA.EU. https:\/\/bit.ly\/3aEU2Na. Accessed 26 Apr 2020"},{"key":"2787_CR25","unstructured":"EMA (2019) Guideline on quality, non-clinical and clinical requirements 5 for investigational advanced therapy medicinal products 6 in clinical trials. EMA\/CAT\/852602\/2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy_en.pdf. Accessed 26 Apr 2020"},{"key":"2787_CR26","unstructured":"EMA (2020a) Update on treatments and vaccines against COVID-19 under development. EMA\/160083\/2020 media and public relations. https:\/\/www.ema.europa.eu\/en\/news\/update-treatments-vaccines-against-covid-19-under-development. Accessed 26 Apr 2020"},{"key":"2787_CR27","unstructured":"EMA (2020b) EMA regulatory science to 2025. EMA\/110706\/2020. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf. Accessed 26 Apr 2020"},{"key":"2787_CR28","unstructured":"EPA (2019) Administrator wheeler signs memo to reduce animal testing, awards $4.25 million to advance research on alternative methods to animal testing. EPA news releases. https:\/\/bit.ly\/2y29ENz. Accessed 26 Apr 2020"},{"issue":"12","key":"2787_CR29","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1007\/s00204-019-02591-7","volume":"93","author":"SE Escher","year":"2019","unstructured":"Escher SE, Kamp H, Bennekou SH et al (2019) Towards grouping concepts based on new approach methodologies in chemical hazard assessment: the read-across approach of the EU-ToxRisk project. Arch Toxicol 93(12):3643\u20133667. https:\/\/doi.org\/10.1007\/s00204-019-02591-7","journal-title":"Arch Toxicol"},{"key":"2787_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-33826-2_1","volume":"856","author":"C Eskes","year":"2016","unstructured":"Eskes C, Whelan M (2016) Introduction. Adv Exp Med Biol 856:1\u20137. https:\/\/doi.org\/10.1007\/978-3-319-33826-2_1","journal-title":"Adv Exp Med Biol"},{"key":"2787_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-pharmtox-010617-052722","volume":"58","author":"L Ewart","year":"2018","unstructured":"Ewart L, Dehne EM, Fabre K et al (2018) Application of microphysiological systems to enhance safety assessment in drug discovery. Annu Rev Pharmacol Toxicol 58:65\u201382. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010617-052722","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2787_CR32","unstructured":"FDA (2017) FDA\u2019s predictive toxicology roadmap. FDA website. https:\/\/bit.ly\/3bCU1e4. Accessed 26 Apr 2020"},{"key":"2787_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.17.046375","author":"Q Gao","year":"2020","unstructured":"Gao Q, Bao L, Mao H et al (2020) Rapid development of an inactivated vaccine for SARS-CoV-2. Biorxiv. https:\/\/doi.org\/10.1101\/2020.04.17.046375","journal-title":"Biorxiv"},{"key":"2787_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.addr.2013.12.011","volume":"69\u201370","author":"C Giese","year":"2014","unstructured":"Giese C, Marx U (2014) Human immunity in vitro\u2014solving immunogenicity and more. Adv Drug Deliv Rev 69\u201370:103\u2013122. https:\/\/doi.org\/10.1016\/j.addr.2013.12.011","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"2787_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1525-1594.2006.00303.x","volume":"30","author":"C Giese","year":"2006","unstructured":"Giese C, Demmler CD, Ammer R et al (2006) A human lymph node in vitro\u2013challenges and progress. Artif Organs 30(10):803\u2013808. https:\/\/doi.org\/10.1111\/j.1525-1594.2006.00303.x","journal-title":"Artif Organs"},{"issue":"5","key":"2787_CR36","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1039\/C5TX00123D","volume":"4","author":"J-Y Goh","year":"2015","unstructured":"Goh J-Y, Weaver RJ, Dixon L, Platt NJ, Roberts RA (2015) Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980\u20132013. Toxicol Res 4(5):1297\u20131307. https:\/\/doi.org\/10.1039\/C5TX00123D","journal-title":"Toxicol Res"},{"issue":"4","key":"2787_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.14573\/altex.1510051","volume":"32","author":"S Gordon","year":"2015","unstructured":"Gordon S, Daneshian M, Bouwstra J et al (2015) Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. Altex 32(4):327\u2013378. https:\/\/doi.org\/10.14573\/altex.1510051","journal-title":"Altex"},{"key":"2787_CR38","first-page":"33","volume":"15","author":"R Graepel","year":"2019","unstructured":"Graepel R, Ter Braak B, Escher SE et al (2019) Paradigm shift in safety assessment using new approach methods: the EU-ToxRisk strategy. Curr Opin Pharmacol 15:33\u201339","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"2787_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tibtech.2016.05.017","volume":"34","author":"AC Gray","year":"2016","unstructured":"Gray AC, Sidhu SS, Chandrasekera PC, Hendriksen CFM, Borrebaeck CAK (2016) Animal-friendly affinity reagents: replacing the needless in the haystack. Trends Biotechnol 34(12):960\u2013969. https:\/\/doi.org\/10.1016\/j.tibtech.2016.05.017","journal-title":"Trends Biotechnol"},{"key":"2787_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tiv.2017.01.004","volume":"41","author":"J Hamm","year":"2017","unstructured":"Hamm J, Sullivan K, Clippinger AJ et al (2017) Alternative approaches for identifying acute systemic toxicity: moving from research to regulatory testing. Toxicol In Vitro 41:245\u2013259. https:\/\/doi.org\/10.1016\/j.tiv.2017.01.004","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"2787_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.14573\/altex.2008.2.91","volume":"25","author":"T Hartung","year":"2008","unstructured":"Hartung T, Leist M (2008) Food for thought \u2026 on the evolution of toxicology and the phasing out of animal testing. Altex 25(2):91\u2013102. https:\/\/doi.org\/10.14573\/altex.2008.2.91","journal-title":"Altex"},{"key":"2787_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14573\/altex.2012.3.251","volume":"29","author":"T Hartung","year":"2012","unstructured":"Hartung T, Zurlo J (2012) Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. Altex 29:251\u2013260","journal-title":"Altex"},{"issue":"2\u20133","key":"2787_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.mrrev.2009.07.002","volume":"682","author":"LG Hernandez","year":"2009","unstructured":"Hernandez LG, van Steeg H, Luijten M, van Benthem J (2009) Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat Res 682(2\u20133):94\u2013109. https:\/\/doi.org\/10.1016\/j.mrrev.2009.07.002","journal-title":"Mutat Res"},{"key":"2787_CR45","unstructured":"ICH (2020) Detection of reproductive and developmental toxicity for human pharmaceuticals S5 (R3). ICH harmonised guideline. https:\/\/bit.ly\/3aDR7EH. Accessed 26 Apr 2020"},{"key":"2787_CR46","unstructured":"ICMRA (2020) Summary report: global regulatory workshop on COVID-19 vaccine development. IMCRA. https:\/\/bit.ly\/3bQEOGg. Accessed 26 Apr 2020"},{"key":"2787_CR47","unstructured":"IMI (2020) IMI planning EUR 45 million call for proposals on COVID-19. IMI newsroom. https:\/\/bit.ly\/2YatQaL. Accessed 26 Apr 2020"},{"issue":"4","key":"2787_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.14573\/altex.1601201","volume":"33","author":"MN Jacobs","year":"2016","unstructured":"Jacobs MN, Colacci A, Louekari K et al (2016) International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances. Altex 33(4):359\u2013392. https:\/\/doi.org\/10.14573\/altex.1601201","journal-title":"Altex"},{"key":"2787_CR49","unstructured":"JHSPH (2020) Infectious disease experts recommend using antibodies from COVID-19 survivors as stopgap measure to treat patients and protect healthcare workers. JHSPH news. https:\/\/bit.ly\/2Y8con9. Accessed 26 Apr 2020"},{"issue":"2","key":"2787_CR50","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00204-019-02642-z","volume":"94","author":"P Kranaster","year":"2020","unstructured":"Kranaster P, Karreman C, Dold J et al (2020) Time and space-resolved quantification of plasma membrane sialylation for measurements of cell function and neurotoxicity. Arch Toxicol 94(2):449\u2013467. https:\/\/doi.org\/10.1007\/s00204-019-02642-z","journal-title":"Arch Toxicol"},{"issue":"17","key":"2787_CR51","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.vaccine.2018.02.078","volume":"36","author":"E Kretzschmar","year":"2018","unstructured":"Kretzschmar E, Muckenfuss H, Pfleiderer M (2018) Official batch control of influenza vaccines: is it still useful? Vaccine 36(17):2364\u20132370. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.078","journal-title":"Vaccine"},{"issue":"2\u20134","key":"2787_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/10937404.2010.483176","volume":"13","author":"D Krewski","year":"2010","unstructured":"Krewski D, Acosta D Jr, Andersen M et al (2010) Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev 13(2\u20134):51\u2013138. https:\/\/doi.org\/10.1080\/10937404.2010.483176","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"2787_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00204-019-02613-4","volume":"94","author":"D Krewski","year":"2020","unstructured":"Krewski D, Andersen M, Tyshenko MG et al (2020) Toxicity testing in the 21st century: progress in the past decade and future perspectives. Arch Toxicol 94:1\u201358. https:\/\/doi.org\/10.1007\/s00204-019-02613-4","journal-title":"Arch Toxicol"},{"key":"2787_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5","author":"T Le Thanh","year":"2020","unstructured":"Le Thanh T, Andreadakis Z, Kumar A et al (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/d41573-020-00073-5","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2787_CR54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00204-013-1038-0","volume":"87","author":"M Leist","year":"2013","unstructured":"Leist M, Hartung T (2013) Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol 87(4):563\u2013567. https:\/\/doi.org\/10.1007\/s00204-013-1038-0","journal-title":"Arch Toxicol"},{"issue":"2","key":"2787_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14573\/altex.2008.2.103","volume":"25","author":"M Leist","year":"2008","unstructured":"Leist M, Hartung T, Nicotera P (2008) The dawning of a new age of toxicology. Altex 25(2):103\u2013114","journal-title":"Altex"},{"issue":"3","key":"2787_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.14573\/altex.1406091","volume":"31","author":"M Leist","year":"2014","unstructured":"Leist M, Hasiwa N, Rovida C et al (2014) Consensus report on the future of animal-free systemic toxicity testing. Altex 31(3):341\u2013356. https:\/\/doi.org\/10.14573\/altex.1406091","journal-title":"Altex"},{"issue":"3","key":"2787_CR57","doi-asserted-by":"publisher","first-page":"272","DOI":"10.14573\/altex.1603161","volume":"33","author":"U Marx","year":"2016","unstructured":"Marx U, Andersson TB, Bahinski A et al (2016) Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. Altex 33(3):272\u2013321. https:\/\/doi.org\/10.14573\/altex.1603161","journal-title":"Altex"},{"key":"2787_CR58","doi-asserted-by":"publisher","DOI":"10.14573\/altex.2001241","author":"U Marx","year":"2020","unstructured":"Marx U, Akabane T, Andersson TB et al (2020) Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. Altex. https:\/\/doi.org\/10.14573\/altex.2001241","journal-title":"Altex"},{"issue":"2","key":"2787_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr","year":"2007","unstructured":"McCray PB Jr, Pewe L, Wohlford-Lenane C et al (2007) Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 81(2):813\u2013821. https:\/\/doi.org\/10.1128\/JVI.02012-06","journal-title":"J Virol"},{"issue":"3","key":"2787_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.14573\/altex.1807041","volume":"35","author":"L Meigs","year":"2018","unstructured":"Meigs L, Smirnova L, Rovida C, Leist M, Hartung T (2018) Animal testing and its alternatives\u2014the most important omics is economics. Altex 35(3):275\u2013305. https:\/\/doi.org\/10.14573\/altex.1807041","journal-title":"Altex"},{"key":"2787_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.004","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P et al (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell J. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell J"},{"key":"2787_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","volume":"334","author":"TM Monticello","year":"2017","unstructured":"Monticello TM, Jones TW, Dambach DM et al (2017) Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database. Toxicol Appl Pharmacol 334:100\u2013109. https:\/\/doi.org\/10.1016\/j.taap.2017.09.006","journal-title":"Toxicol Appl Pharmacol"},{"key":"2787_CR63","unstructured":"Murphy T (2020) Why researchers think HIV meds might work against COVID-19. The body pro. https:\/\/bit.ly\/354VwPG. Accessed 26 Apr 2020"},{"key":"2787_CR64","volume-title":"Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. The National Academies Collection: Reports funded by National Institutes of Health","author":"NAS","year":"2011","unstructured":"NAS (2011) Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. The National Academies Collection: Reports funded by National Institutes of Health. Institute of Medicine (US) and National Research Council (US) Committee on the Use of Chimpanzees in Biomedical and Behavioral Research, Washington (DC)"},{"key":"2787_CR65","doi-asserted-by":"crossref","unstructured":"NRC (2007) Toxicity testing in the 21st century: a vision and a strategy. The National Academies Press, Washington, DC. https:\/\/doi.org\/10.17226\/11970","DOI":"10.17226\/11970"},{"key":"2787_CR66","doi-asserted-by":"crossref","unstructured":"NRC (2011) Animal models for assessing countermeasures to bioterrorism agents. The National Academies Press, Washington, DC. https:\/\/doi.org\/10.17226\/13233","DOI":"10.17226\/13233"},{"issue":"1","key":"2787_CR67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson H, Betton G, Robinson D et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56\u201367. https:\/\/doi.org\/10.1006\/rtph.2000.1399","journal-title":"Regul Toxicol Pharmacol"},{"key":"2787_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040171","author":"SS Park","year":"2019","unstructured":"Park SS (2019) Post-glycosylation modification of sialic acid and its role in virus pathogenesis. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines7040171","journal-title":"Vaccines (Basel)"},{"issue":"19","key":"2787_CR69","doi-asserted-by":"publisher","first-page":"7797","DOI":"10.1074\/jbc.RA119.007532","volume":"294","author":"LM Parsons","year":"2019","unstructured":"Parsons LM, Bouwman KM, Azurmendi H, de Vries RP, Cipollo JF, Verheije MH (2019) Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding. J Biol Chem 294(19):7797\u20137809. https:\/\/doi.org\/10.1074\/jbc.RA119.007532","journal-title":"J Biol Chem"},{"key":"2787_CR70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coph.2018.08.007","volume":"42","author":"J Pinero","year":"2018","unstructured":"Pinero J, Furlong LI, Sanz F (2018) In silico models in drug development: where we are. Curr Opin Pharmacol 42:111\u2013121. https:\/\/doi.org\/10.1016\/j.coph.2018.08.007","journal-title":"Curr Opin Pharmacol"},{"key":"2787_CR71","unstructured":"Roberts M (2020) Coronavirus: US volunteers test first vaccine. BBC news. https:\/\/bbc.in\/33XZFnY. Accessed 26 Apr 2020"},{"key":"2787_CR72","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.3389\/fimmu.2018.02634","volume":"9","author":"G Sanchez-Schmitz","year":"2018","unstructured":"Sanchez-Schmitz G, Stevens CR, Bettencourt IA et al (2018) Microphysiologic human tissue constructs reproduce autologous age-specific BCG and HBV primary immunization in vitro. Front Immunol 9:2634. https:\/\/doi.org\/10.3389\/fimmu.2018.02634","journal-title":"Front Immunol"},{"issue":"2","key":"2787_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ilar\/ilw024","volume":"57","author":"F Sewell","year":"2016","unstructured":"Sewell F, Edwards J, Prior H, Robinson S (2016) Opportunities to apply the 3Rs in safety assessment programs. ILAR J 57(2):234\u2013245. https:\/\/doi.org\/10.1093\/ilar\/ilw024","journal-title":"ILAR J"},{"issue":"D1","key":"2787_CR74","doi-asserted-by":"publisher","first-page":"D1080","DOI":"10.1093\/nar\/gkv1192","volume":"44","author":"VB Siramshetty","year":"2016","unstructured":"Siramshetty VB, Nickel J, Omieczynski C, Gohlke BO, Drwal MN, Preissner R (2016) WITHDRAWN\u2014a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44(D1):D1080\u2013D1086. https:\/\/doi.org\/10.1093\/nar\/gkv1192","journal-title":"Nucleic Acids Res"},{"key":"2787_CR75","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.yrtph.2018.01.022","volume":"94","author":"J Strickland","year":"2018","unstructured":"Strickland J, Clippinger AJ, Brown J et al (2018) Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies. Regul Toxicol Pharmacol 94:183\u2013196. https:\/\/doi.org\/10.1016\/j.yrtph.2018.01.022","journal-title":"Regul Toxicol Pharmacol"},{"issue":"12","key":"2787_CR76","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/nbt1039","volume":"22","author":"S Suematsu","year":"2004","unstructured":"Suematsu S, Watanabe T (2004) Generation of a synthetic lymphoid tissue-like organoid in mice. Nat Biotechnol 22(12):1539\u20131545. https:\/\/doi.org\/10.1038\/nbt1039","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2787_CR77","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2131\/jts.38.581","volume":"38","author":"C Tamaki","year":"2013","unstructured":"Tamaki C, Nagayama T, Hashiba M et al (2013) Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J Toxicol Sci 38(4):581\u2013598. https:\/\/doi.org\/10.2131\/jts.38.581","journal-title":"J Toxicol Sci"},{"issue":"2","key":"2787_CR79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.14573\/altex.1803011","volume":"35","author":"RS Thomas","year":"2018","unstructured":"Thomas RS, Paules RS, Simeonov A et al (2018) The US federal Tox21 program: a strategic and operational plan for continued leadership. Altex 35(2):163\u2013168. https:\/\/doi.org\/10.14573\/altex.1803011","journal-title":"Altex"},{"issue":"7","key":"2787_CR80","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1289\/ehp.1205784","volume":"121","author":"RR Tice","year":"2013","unstructured":"Tice RR, Austin CP, Kavlock RJ, Bucher JR (2013) Improving the human hazard characterization of chemicals: a Tox21 update. Environ Health Perspect 121(7):756\u2013765. https:\/\/doi.org\/10.1289\/ehp.1205784","journal-title":"Environ Health Perspect"},{"issue":"6","key":"2787_CR81","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","volume":"26","author":"MA Tortorici","year":"2019","unstructured":"Tortorici MA, Walls AC, Lang Y et al (2019) Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol 26(6):481\u2013489. https:\/\/doi.org\/10.1038\/s41594-019-0233-y","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"2787_CR82","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","volume":"18","author":"J Vamathevan","year":"2019","unstructured":"Vamathevan J, Clark D, Czodrowski P et al (2019) Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 18(6):463\u2013477. https:\/\/doi.org\/10.1038\/s41573-019-0024-5","journal-title":"Nat Rev Drug Discov"},{"key":"2787_CR83","unstructured":"Wheaton S (2020) Von der Leyen hopes for vaccine by \u2018autumn,\u2019 defying expert predictions. Politico. https:\/\/politi.co\/39rIAUR. Accessed 26 Apr 2020"},{"key":"2787_CR84","unstructured":"WHO (2003) WHO expert committee on biological standardization: fifty-fourth report. WHO technical report series 927 (ISBN 92 4 120927 5)"},{"key":"2787_CR85","doi-asserted-by":"publisher","unstructured":"Zuang V, Dura A, Asturiol Bofill D, et al (2019) EURL ECVAM status report on the development, validation and regulatory acceptance of alternative methods and approaches. Publications office of the European Union, Luxembourg. https:\/\/doi.org\/10.2760\/25602JRC119292 (ISBN 978-92-76-16368-8)","DOI":"10.2760\/25602JRC119292"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-020-02787-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T23:09:00Z","timestamp":1621724940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-020-02787-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2787"],"URL":"https:\/\/doi.org\/10.1007\/s00204-020-02787-2","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TH is named inventor on a patent by Johns Hopkins University on the production of mini-brains (also called BrainSpheres), which is licensed to AxoSim, New Orleans, LA, USA. He consults AxoSim and is a shareholder.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}